Cymbalta User Fee Date Extended; Lilly Still Expects Summer Launch
This article was originally published in The Pink Sheet Daily
Executive Summary
Duloxetine now has a late September FDA action date, triggered by Lilly’s submission of new data analyses to support depression indication.